Portola Pharmaceuticals Inc (NASDAQ:PTLA) – Oppenheimer lowered their FY2020 EPS estimates for shares of Portola Pharmaceuticals in a research note issued on Wednesday. Oppenheimer analyst J. Olson now expects that the biopharmaceutical company will earn $3.47 per share for the year, down from their prior estimate of $3.48. Oppenheimer has a “Buy” rating and a $80.00 price objective on the stock.

Several other analysts have also weighed in on the company. Morgan Stanley reaffirmed an “overweight” rating and issued a $81.00 price objective (up from $75.00) on shares of Portola Pharmaceuticals in a research note on Friday, October 6th. Credit Suisse Group raised Portola Pharmaceuticals from a “neutral” rating to an “outperform” rating and set a $70.00 price objective on the stock in a research note on Wednesday, August 23rd. Goldman Sachs Group initiated coverage on Portola Pharmaceuticals in a research note on Friday, December 1st. They issued a “buy” rating and a $75.00 price objective on the stock. Finally, BidaskClub lowered Portola Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research note on Thursday, December 7th. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating and nine have assigned a buy rating to the company’s stock. The company presently has an average rating of “Buy” and a consensus target price of $71.15.

Shares of Portola Pharmaceuticals (NASDAQ:PTLA) opened at $47.02 on Friday. The company has a quick ratio of 8.31, a current ratio of 8.31 and a debt-to-equity ratio of 0.24. Portola Pharmaceuticals has a 12 month low of $18.30 and a 12 month high of $67.10.

Portola Pharmaceuticals (NASDAQ:PTLA) last released its quarterly earnings data on Monday, November 6th. The biopharmaceutical company reported ($1.41) earnings per share for the quarter, beating the consensus estimate of ($1.49) by $0.08. The business had revenue of $3.83 million for the quarter, compared to analyst estimates of $4.71 million. Portola Pharmaceuticals had a negative return on equity of 110.46% and a negative net margin of 938.19%. Portola Pharmaceuticals’s revenue was down 58.9% compared to the same quarter last year. During the same period last year, the firm posted ($1.64) earnings per share.

Several hedge funds have recently made changes to their positions in the company. Hanseatic Management Services Inc. boosted its stake in shares of Portola Pharmaceuticals by 0.3% during the second quarter. Hanseatic Management Services Inc. now owns 22,800 shares of the biopharmaceutical company’s stock valued at $1,281,000 after purchasing an additional 70 shares in the last quarter. IFP Advisors Inc boosted its stake in shares of Portola Pharmaceuticals by 7.7% during the second quarter. IFP Advisors Inc now owns 2,370 shares of the biopharmaceutical company’s stock valued at $133,000 after purchasing an additional 170 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank boosted its stake in shares of Portola Pharmaceuticals by 14.2% during the second quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 2,078 shares of the biopharmaceutical company’s stock valued at $117,000 after purchasing an additional 258 shares in the last quarter. Amalgamated Bank boosted its stake in shares of Portola Pharmaceuticals by 5.4% during the second quarter. Amalgamated Bank now owns 6,376 shares of the biopharmaceutical company’s stock valued at $358,000 after purchasing an additional 328 shares in the last quarter. Finally, Principal Financial Group Inc. boosted its stake in shares of Portola Pharmaceuticals by 0.6% during the second quarter. Principal Financial Group Inc. now owns 62,693 shares of the biopharmaceutical company’s stock valued at $3,521,000 after purchasing an additional 371 shares in the last quarter. 87.45% of the stock is currently owned by hedge funds and other institutional investors.

COPYRIGHT VIOLATION NOTICE: “FY2020 EPS Estimates for Portola Pharmaceuticals Inc (PTLA) Lowered by Oppenheimer” was originally posted by Watch List News and is the property of of Watch List News. If you are accessing this news story on another publication, it was illegally stolen and republished in violation of United States and international copyright and trademark laws. The correct version of this news story can be viewed at https://www.watchlistnews.com/fy2020-eps-estimates-for-portola-pharmaceuticals-inc-ptla-lowered-by-oppenheimer/1769392.html.

Portola Pharmaceuticals Company Profile

Portola Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics in the areas of thrombosis, other hematologic disorders and inflammation for patients having limited or no approved treatment options. The Company’s two lead programs, Betrixaban and Andexanet alfa, address unmet medical needs in the area of thrombosis, or blood clots.

Earnings History and Estimates for Portola Pharmaceuticals (NASDAQ:PTLA)

Receive News & Ratings for Portola Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Portola Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.